FDA
-
-
-
-
-
-
-
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
-
-
-
-
-
-
-
Aquestive completes FDA meeting on Anaphylm drug application
-
-
-
-
-
-
-
AQST Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Aquestive Therapeutics, Inc. Securities Class Action Lawsuit — The Gross Law Firm
-
-
-
-
-
-
-
Aquestive Therapeutics names Matthew Greenhawt as chief medical officer
-
-
-
-
-
-
-
Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update
-
-
-
-
-
-
-
Aquestive says FDA won't require advisory meeting for Anaphylm drug
-
-
-
-
-
-
-
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
-
332,024 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

